Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
The force awakens: insights into the origin and formation of microglia.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Keystone Symposium: Viral Immunity
Immunology 2015
Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
MS Frontiers 2015
“Human Medicines” page
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Episode 13 with Professor Alan Thompson on the International Progressive MS Alliance.
Episode 31 with Dr. Lloyd Kasper on the gut microbiome and MS
Neuroprotective effects of resident microglia following acute brain injury.
Mechanism of action of mitoxantrone.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Webinar: "Seeking Best Practices in Classifier Construction and Testing"
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Avonex approval application
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Interleukin-1beta promotes repair of the CNS.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis

Pages

« first
‹ previous
…
58
59
60
61
62
63
64
65
66
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By